EQS-News: Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
BERKELEY, US – MAINZ, Germany – DECEMBER 12, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) detection and gastroenterological innovation.
- BERKELEY, US – MAINZ, Germany – DECEMBER 12, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) detection and gastroenterological innovation.
- The first attended conference, the 17th Conference: Advances in Gastroenterology, ran from December 8th to 9th, 2023, in Poznań.
- Following this, Mainz Biomed will be taking part in the 10th Gdańsk Gastroenterology Symposium which runs from January 12th to 13th, 2024.
- Darin Leigh, Chief Commercial Officer of Mainz Biomed, expressed enthusiasm about the upcoming conferences, stating, "Our collaboration with TestDNA at these prestigious conferences is a testament to our shared commitment to revolutionize CRC detection and improve patient outcomes.